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Post hoc analyses of SHIFT and PARADIGM-HF
highlight the importance of chronic Chagas’
cardiomyopathy
Comment on:
“Safety proﬁle and efﬁcacy of ivabradine in heart
failure due to Chagas heart disease: a post hoc analysis
of the SHIFT trial” by Bocchi et al.
We read with interest the report by Bocchi and colleagues of
their post hoc analysis of the Systolic Heart failure treatment
with the If inhibitor ivabradine Trial (SHIFT), examining the
effect of study drug in the 38 patients with chronic chagasic
cardiomyopathy (CCC).1
The authors reported that study drug lowered heart rate
and improved New York Heart Association class. The sample
size was too small to allow estimation of the effect of treat-
ment on mortality or hospitalization. However, this analysis
did suggest that patients with CCC experienced high event
rates, despite excellent background therapy.
We examined outcomes in patients with CCC in the
Prospective comparison of Angiotensin Receptor Neprilysin
Inhibitor with Angiotensin Converting Enzyme Inhibitor to
Determine Impact on Global Mortality and morbidity in
Heart Failure (PARADIGM-HF) and the Aliskiren trial to
Minimize OutcomeS in Patients with Heart failure
(ATMOSPHERE).2,3
These trials included 195 CCC patients from among a total
of 2552 recruited in Latin America. Despite being younger
and having less co-morbidity, the CCC patients had higher
hospitalization and mortality rates, compared with other
aetiologies, despite similarly good treatment.4
We also conducted an exploratory post hoc analysis of the
effect of sacubitril/valsartan (formerly known as LCZ696) in
CCC patients in PARADIGM-HF. Of a total of 113 patients,
58 were randomized to sacubitril/valsartan and 55 to enala-
pril. The two treatment groups were similar in terms of de-
mographics, co-morbidity, and heart failure (HF) severity.
Patients with CCC treated with sacubitril/valsartan, as com-
pared with enalapril, had a lower risk of experiencing cardio-
vascular death or HF hospitalization, the primary composite
endpoint, and each of its components (Figure). The point es-
timate for risk reduction was comparable with or greater
than that seen with the drug vs. enalapril in the entire study
population. This analysis is underpowered and should be
interpreted with caution.
CCC is a major health issue in Latin America and is now
recognized in the USA and Europe, reﬂecting contemporary
migration patterns.5–8 Indeed, a recent study from Brazil con-
cluded that the population attributable mortality risk from
CCC increased between 2002/2004 and 2012/2014.9 Future
trials should consider recruiting larger numbers of patients
with CCC to allow adequately powered subgroup analysis
and even trials speciﬁcally in CCC would be justiﬁed, given
the magnitude of this problem. Until that time, patients with
CCC should be treated empirically with therapies recom-
mended by guidelines, on the assumption that treatments
for patients with reduced ejection fraction are effective, irre-
spective of aetiology of HF.
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